Brazil Potash Achieved Major 2025 Milestones, Positions for Construction Advancement in 2026

Brazil Potash Achieved Major 2025 Milestones, Positions for Construction Advancement in 2026 GlobeNewswire December 08, 2025 Signed Contracts to Sell ~91% of Production, Strengthened Leadership Team, Advanced Site Preparation and Community Partnerships 2026 Focus on Construction Financing, Completing Advanced Engineering, Indigenous Impact Benefit Agreement, and Strategic Partnerships CEO Matt Simpson to outline company progress and […]

How Fenstermaker Uses Handheld Lidar to Map Schools for 911 Safety and Response

How Fenstermaker Uses Handheld Lidar to Map Schools for 911 Safety and Response Fenstermaker, NEI, and Lafayette Parish 911 use the TrueView GO to Create Digital School Maps that Give First Responders a Head Start When Seconds Count GlobeNewswire December 08, 2025 Huntsville, AL, Dec. 08, 2025 (GLOBE NEWSWIRE) — GeoCue announces the premiere of

Westwood Holdings Group, Inc. Recognized in Pensions & Investments’ Best Places to Work in Money Management

Westwood Holdings Group, Inc. Recognized in Pensions & Investments' Best Places to Work in Money Management GlobeNewswire December 08, 2025 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — Westwood Holdings Group, Inc. was recognized in the 2025 Best Places to Work in Money Management awards announced by Pensions & Investments today. Presented by Pensions &

Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting GlobeNewswire December 08, 2025 Presented new data in non-human primates (NHP) for sickle cell disease (SCD), where RNA Gene Writer achieved approximately 40% and 60% of

RESTEM Announces First-Patient-Dosed in the Phase 1/2a Study of Restem-L in Facioscapulohumeral Muscular Dystrophy

RESTEM Announces First-Patient-Dosed in the Phase 1/2a Study of Restem-L in Facioscapulohumeral Muscular Dystrophy GlobeNewswire December 08, 2025 âˆ' First patient with facioscapulohumeral muscular dystrophy (FSHD) dosed with Restem-L umbilical lining modified progenitor cells (UMPCs) âˆ' The Phase 1/2a study will evaluate the safety and preliminary efficacy of Restem-L in patients with FSHD âˆ' Clinical

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Arrival SA and/or CIIG Merger Corp. – ARVLF

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Arrival SA and/or CIIG Merger Corp. – ARVLF GlobeNewswire December 08, 2025 BROOKLYN, N.Y., Dec. 08, 2025 (GLOBE NEWSWIRE) — The Rosen Law Firm, P.A. announces that the United States District Court for the Eastern District of New

ASML reports transactions under its current share buyback program

ASML reports transactions under its current share buyback program GlobeNewswire December 08, 2025 ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. Date Total repurchased shares Weighted average price Total repurchased value 01-Dec-25 39,527 EUR915.08 EUR36,170,185

Rocket Doctor AI, Health Cities and CAN Health Network Partner to Advance AI-Powered Clinical Decision Support in Alberta

Rocket Doctor AI, Health Cities and CAN Health Network Partner to Advance AI-Powered Clinical Decision Support in Alberta GlobeNewswire December 08, 2025 Rocket Doctor AI joins forces with the CAN Health Network to deliver an AI-powered Clinical Decision Support System (CDSS) in collaboration with Health Cities Alberta. Initial rollout will take place at up to

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenstrom Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenstrom Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire December 08, 2025 Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenstrom macroglobulinemia patients With a median follow

Suburban Propane Partners, L.P. Announces Proposed Private Offering of Senior Notes

Suburban Propane Partners, L.P. (NYSE: SPH) (“Suburban Propane”) announced today that it intends, subject to market conditions, to offer $350,000,000 aggregate principal amount of senior notes due 2035 (the “2035 Senior Notes”) in a private placement not registered under the Securities Act of 1933, as amended (the “Securities Act”). Suburban Energy Finance Corp., a wholly

Scroll to Top